Article Details

Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the ...

Retrieved on: 2021-11-16 14:49:21

Tags for this article:

Click the tags to see associated articles and topics

Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the .... View article details on hiswai:

Excerpt

SEATTLE, Nov. 16, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in ...

Article found on: www.khq.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up